FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

Abstract Biomarkers to identify patients without benefit from adding everolimus to endocrine treatment in metastatic breast cancer (MBC) are needed. We report the results of the Pearl trial conducted in five Belgian centers assessing 18F-FDG-PET/CT non-response (n = 45) and ctDNA detection (n = 46)...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Andrea Gombos, David Venet, Lieveke Ameye, Peter Vuylsteke, Patrick Neven, Vincent Richard, Francois P. Duhoux, Jean-Francois Laes, Françoise Rothe, Christos Sotiriou, Marianne Paesmans, Ahmad Awada, Thomas Guiot, Patrick Flamen, Martine Piccart-Gebhart, Michail Ignatiadis, Géraldine Gebhart
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Portfolio 2021-09-01
Serie:	npj Breast Cancer
Accesso online:	https://doi.org/10.1038/s41523-021-00331-8
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!